BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 10, 2008
View Archived Issues
Tumor responses associated with PARP inhibition seen in phase I studies with BSI-201
Read More
Semafore reports positive interim results from phase I study of PI3K inhibitor SF-1126
Read More
Recent patents impart novel compounds for respiratory disorders
Read More
Akorn receives FDA approvable letter for Akten ophthalmic gel 3.5%
Read More
PAC-113 found effective in the treatment of oral candidiasis in phase IIb dose-ranging trial
Read More
New treatment options for neuropsychiatric disorders imparted in recent patents
Read More
BTG completes treatments in Varisolve U.S. phase II safety study
Read More
Update on clinical studies of Boehringer Ingelheim's Polo-like kinase inhibitor BI-2536
Read More
AMANET launches large-scale testing of MSP3-LSP malaria vaccine candidate
Read More
FDA grants pediatric exclusivity to UCB's Keppra until January 2009
Read More
Prucalopride found safe and effective in patients with chronic constipation
Read More
First-in-human results with antisense oligonucleotide LY-2181308 for the treatment of solid tumors
Read More
Oncolytics initiates enrollment in phase II trial of Reolysin with paclitaxel and carboplatin
Read More
Sirtris' novel SIRT1 activator shows efficacy in mouse models of type 2 diabetes
Read More
Akesis completes recruitment and dosing in phase IIa trial of AKP-020 in type 2 diabetes
Read More
BioMarin to initiate phase I/II trial in the first quarter of 2009 of new ERT for MPS IVA
Read More
Anesiva and TFT enter licensing agreement for NF-kappa B clinical program
Read More
Genocea Biosciences and PATH enter collaboration agreement to develop pneumoccocus vaccine
Read More
Gentium presents update on DSMB reviews of phase II/III and phase III trials of defibrotide
Read More
Inspire achieves primary endpoint in phase III denufosol trial in cystic fibrosis
Read More
Vertex reports 52% SVR 12 rate for a 24-week telaprevir-based regimen in HCV
Read More
Targanta Therapeutics submits MAA to EMEA for oritavancin
Read More
